Transfer pricing at heart of Pfizer case
Shareholders allege that Pfizer has deliberately contributed to poor results at its Pakistan operations, thus diluting the value of the minority stakeholders’ shares
Reply to comment
i must congrutulate u fr showing the ugly face of the multinationals and exposing the nefarious methods of downright robbing the people of the thirld world. minority shareholders may be compensated, but what about the millions of patients like myself(i am taking norvasc),what remedy is available to me. exploitation by pharmaceuticals is a world wide menace to mankind.
khalid